中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
22期
26-28
,共3页
胰岛素%2型糖尿病%冠心病%磷酸西格列汀
胰島素%2型糖尿病%冠心病%燐痠西格列汀
이도소%2형당뇨병%관심병%린산서격렬정
Insulin%Type 2 diabetes%Coronary heart disease%Sitagliptin phosphate
目的 观察磷酸西格列汀对胰岛素控制不佳的2型糖尿病并冠心病患者的疗效与安全性.方法 选38例使用胰岛素血糖控制不佳的2型糖尿病并冠心病患者,加用磷酸西格列汀100 mg,每天1次,口服.根据血糖监测情况调整胰岛素用量,了解血糖、糖化血红蛋白、血压、体质量及低血糖发生情况.并观察心电图、血常规、肝肾功能、血脂变化.结果 治疗期间1例因皮肤瘙痒用抗过敏药效果不佳停用磷酸西格列汀,观察实际为37例,治疗后3个月血糖水平及糖化血红蛋白及胰岛素用量均下降,与治疗前比较差异有统计学意义(P＜0.05);体质量、血压改变与治疗前比较差异无统计学意义(P＞0.05).同时观察到心电图、血脂、肝肾功能、血常规无明显变化.结论 胰岛素控制不佳的2型糖尿病并冠心病患者加用磷酸西格列汀治疗有效、安全,可以减少胰岛素用量.
目的 觀察燐痠西格列汀對胰島素控製不佳的2型糖尿病併冠心病患者的療效與安全性.方法 選38例使用胰島素血糖控製不佳的2型糖尿病併冠心病患者,加用燐痠西格列汀100 mg,每天1次,口服.根據血糖鑑測情況調整胰島素用量,瞭解血糖、糖化血紅蛋白、血壓、體質量及低血糖髮生情況.併觀察心電圖、血常規、肝腎功能、血脂變化.結果 治療期間1例因皮膚瘙癢用抗過敏藥效果不佳停用燐痠西格列汀,觀察實際為37例,治療後3箇月血糖水平及糖化血紅蛋白及胰島素用量均下降,與治療前比較差異有統計學意義(P＜0.05);體質量、血壓改變與治療前比較差異無統計學意義(P＞0.05).同時觀察到心電圖、血脂、肝腎功能、血常規無明顯變化.結論 胰島素控製不佳的2型糖尿病併冠心病患者加用燐痠西格列汀治療有效、安全,可以減少胰島素用量.
목적 관찰린산서격렬정대이도소공제불가적2형당뇨병병관심병환자적료효여안전성.방법 선38례사용이도소혈당공제불가적2형당뇨병병관심병환자,가용린산서격렬정100 mg,매천1차,구복.근거혈당감측정황조정이도소용량,료해혈당、당화혈홍단백、혈압、체질량급저혈당발생정황.병관찰심전도、혈상규、간신공능、혈지변화.결과 치료기간1례인피부소양용항과민약효과불가정용린산서격렬정,관찰실제위37례,치료후3개월혈당수평급당화혈홍단백급이도소용량균하강,여치료전비교차이유통계학의의(P＜0.05);체질량、혈압개변여치료전비교차이무통계학의의(P＞0.05).동시관찰도심전도、혈지、간신공능、혈상규무명현변화.결론 이도소공제불가적2형당뇨병병관심병환자가용린산서격렬정치료유효、안전,가이감소이도소용량.
Objective To observe the effect of sitagliptin phosphate on poor insulin control of type 2 diabetes and coronary heart disease.Methods Thirty-eight cases of poor insulin control of type 2 diabetes and coronary heart disease patients were given sitagliptin phosphate,100 mg,once a day,orally.The insulin dosage was adjusted according to the monitoring of blood glucose,and the blood glucose,glycosylated hemoglobin,blood pressure,body weight and incidence of hypoglycemia was observed.And the changes of ECG,blood routine,liver and kidney function and blood lipid was observed.Results One case stop ped taking sitagliptin phosphate because of skin pruritus during treatment with anti allergy medicine.So there were thirty-seven patients in this study,the blood glucose and glycosylated hemoglobin and insulin dosage decreased 3 months after treatment than before treatment (P ＜ 0.05) ; The body weight and blood pressure after treatment had no significant difference compared with those before treatment (P ＞0.05).At the same time,ECG,blood lipid,liver and renal function,blood routine test also showed no obvious change.Conclusions Sitagliptin phosphate in treatment of poor controll type 2 diabetes and coronary heart disease is effective and safe,and the dosage of insulin can be reduced.
